GlobalData analysed the number of clinical trials of both industry and non-industry-sponsored trials with start dates between January 2019 and December 2019.
GlobalData analysed trials with industry and non-industry sponsors. Figure 1 shows that overall non-industry sponsors conducted more trials than industry sponsors in 2019. Industry sponsors conducted the highest percentage of trials in Q4 at 46.9%, whereas non-industry sponsors had the highest percentage of trials in Q1 at 67.6%.
After further analysis, Novartis had conducted the highest amount of trials in 2019 for an industry sponsor, whereas Cairo University had conducted the most amount of trials for a non-industry sponsor. Industry-sponsored trials were the lowest in Q3 at 32.9% and non-industry-sponsored trials were the lowest in Q4 at 53.1%. Overall the US had conducted the highest amount of trials for 2019, followed by China.